SEARCH:   Advanced

Blood, 15 January 2008, Vol. 111, No. 2, pp. 504-516. Prepublished online as a Blood First Edition Paper on October 4, 2007; DOI 10.1182/blood-2007-07-101899. This Article Full Text (PDF) All Versions of this Article: blood-2007-07-101899v1 111/2/504    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kwee, T. C. Articles by Nievelstein, R. A.J. Search for Related Content PubMed PubMed Citation Articles by Kwee, T. C. Articles by Nievelstein, R. A.J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 31, 2007 Accepted October 2, 2007 Imaging in staging of malignant lymphoma: a systematic review Thomas C. Kwee*, Robert M. Kwee, and Rutger A.J. Nievelstein Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands Department of Radiology, Academic Hospital Maastricht, Maastricht, Netherlands * Corresponding author; email: thomaskwee{at}gmail.com. Computed tomography (CT) is currently the most commonly used means for staging malignant lymphoma. 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET), FDG-PET/CT fusion, and whole-body magnetic resonance imaging (WB-MRI) are potential alternatives. The purpose of this study was to systematically review published data on the diagnostic performance of CT, FDG-PET, FDG-PET/CT fusion, and WB-MRI in staging of malignant lymphoma. In addition, technical aspects, procedures, advantages, and drawbacks of each imaging modality are outlined. Nineteen studies were included in this systematic review: 3 CT studies, 17 FDG-PET studies, and 4 FDG-PET/CT fusion studies. The studies were of moderate methodological quality and used different scoring systems to stage malignant lymphoma. CT remains the standard imaging modality for initial staging of malignant lymphoma, while FDG-PET has an essential role in restaging after treatment. Early results suggest that FDG-PET/CT fusion outperforms both CT alone and FDG-PET alone. Data on the diagnostic performance of WB-MRI are lacking. Future well-designed studies, expressing their results according to the Ann Arbor staging system, are needed to determine which imaging modality is most accurate and cost-effective in staging malignant lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 30 - 40. [Abstract] [Full Text] [PDF] A. K. Buck, M. Bommer, M. E. Juweid, G. Glatting, S. Stilgenbauer, F. M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Moller, et al. First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine J. Nucl. Med., November 1, 2008; 49(11): 1756 - 1762. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020